ClinVar Miner

Submissions for variant NM_004444.5(EPHB4):c.2424dup (p.Val809fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV004018265 SCV004847289 pathogenic Capillary malformation-arteriovenous malformation syndrome 2024-02-09 criteria provided, single submitter clinical testing The p.Val809CysfsX26 variant in EPHB4 was identified through WGS analysis in an adult with liver arteriovenous malformation, skin telangiectasias, and epistaxis by the Broad Institute Rare Genomes Project. It was absent from large population studies. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 809 and leads to a premature termination codon 26 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the EPHB4 gene is an established disease mechanism in autosomal dominant CM-AVM. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant CM-AVM. ACMG/AMP Criteria applied: PVS1, PS4_Supporting, PM2_Supporting.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.